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Background
In Austria, 98% of the population is covered by (statutory)
health insurance. The HVB (Main Association of Austrian
Social Security Institutions) publishes the Reimbursement
Code (EKO) for outpatient medicines, and if new medi-
cines are submitted for inclusion, these are subjected to
pharmacological, medical/therapeutic and health eco-
nomic evaluation. Providing modern and comprehensive
medical care is inevitably and causally linked to a constant
rise in health care costs. Treatment of pain has a unique
position in every health care system, because it is asso-
ciated with many diseases of varying severity. Pain patients
are confronted both with severe and disabling physical as
well as psychological burdens.
Methods
Data were provided by the internal data warehouse of the
HVB, which houses reimbursement data for ambulatory
care from 2001 to 2009. In this study we concentrated on
the analysis of prescribed DDDs (Defined Daily Doses).
Pain medication (as available in the EKO) was grouped
according to the WHO defined scheme for treatment of
pain (1986) into 3 groups. Aims: First, we aimed to discover
changes in prescribing habits. Next, we hoped to learn if
and how either greater availability or the restriction of pain
medication (e.g. the introduction of generics, the waiving of
prescription fees, published severe safety concerns etc,)
influence the rate of utilization of pain medication.
Results
We noticed a difference in the development of the 3
groups: prescribed DDDs of pain medication attributable
to WHO stage 1 and 2 show a slight increase from 2003
to 2009 (19% and 22%, respectively). This is followed by
a divergent development in the next period: for WHO
stage 1, a decrease of prescribed DDDs was noted
(−4.6%), whereas there was no marked change for WHO
stage 2 (−0.3%). In clear contrast, there was a continu-
ous and significant increase in prescribed DDDs of
WHO stage 3 medications, with DDDs almost doubling.
To summarize (2003 to 2010): WHO stage 1: +14%
(127.5 mil. DDDs), WHO stage 2: +21% (13.8 mil.
DDDs), WHO stage 3: +144% (13.4 mil. DDDs).
Conclusions
So far we can say that the analysis of prescribed DDDs
and their allocation into 3 groups – as defined by the
WHO scheme for pain treatment – is a useful tool to
assess changes in prescribing habits. Next we will try to
find out if it can be deduced from our data i) if and
how prescribers follow current guidelines, ii) if safety
concerns or iii) the introduction of innovative therapies
are translated into changes in prescribing habits.
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